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Early intervention in schizophrenia
Introduction
Schizophrenia affects young adults of both sexes
with an incidence of approximately 5 in 1000 people
in the general population.1 The illness produces deva-
stating effects on the subjective experiences of patients
in the form of hallucinations and delusions (psychotic
episodes). In addition, schizophrenia also leads to
lasting behavioural deterioration similar to the changes
seen in patients with gross prefrontal lesions; changes
include disinhibition of behaviour, loss of drive, social
withdrawal, and a loss of emotional expression (the
latter three are termed ‘negative symptoms’). These
effects lead to devastating long-term functional con-
sequences for patients. Furthermore, schizophrenic
patients suffer from severe cognitive deficits such as
attention, memory, and executive function impair-
ments.2 These deficits are persistent and may critically
affect the occupational capacity of patients.
Schizophrenia also tends to have a relapsing
course.3 There is evidence that after each relapse,
some patients have difficulty in returning to their
previous level of functioning.4 Maintaining anti-
psychotic medication is known to be effective against
relapses. Unfortunately, a proportion of patients pro-
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This review examines the clinical and theoretical evidence justifying early intervention in individuals
with schizophrenia. Potential reasons for the previous lack of emphasis on early intervention are discussed.
Interventions that target psychosis are distinguished from those that work on prodromal symptoms. It is
suggested that early intervention programmes should try to reduce the duration of untreated psychosis.
The relationship between this and outcome is discussed. Improving service accessibility alone may not be
sufficient, and education and destigmatisation input may be required. Once a patient is identified, vigorous
pharmacological and psychosocial interventions are important to improve the long-term clinical outcome.
An effective early intervention programme for psychosis provides a basis for the future development of a
prodrome intervention programme.
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gress during the course of their illness to become
resistant to antipsychotic treatment.5
The principle of early intervention
Awareness of the need for early intervention is well-
developed for progressive diseases (eg tumour) in
which a delay in treatment carries conspicuous penal-
ties in terms of mortality and morbidity. But until recently,
awareness has been surprisingly underemphasised in
the management of schizophrenia. This shortcoming
may be related to a prevailing view of schizophrenia
as a developmental disorder exhibiting a static course.6
This view has been challenged with the observation
that, at least for some patients, the illness runs a pro-
gressive course, and that medication might protect
against such progression.7-10 Another reason for a lack
of intervention may be the belief that negative symp-
toms (and hence functional outcome) are not responsive
to antipsychotic treatment.11 Recent studies suggest,
however, that some negative symptoms may improve
with antipsychotic treatment.12 In addition, effective
psychological and social management methods (eg
family therapy) are now recognised. Last but not least,
the period of psychosis is associated with a multitude
of risks and suffering for the individual, the family,
and the community. Consequences can include the lost
opportunity for normal life experience and personal
development, as well as the adverse social consequences
from any psychotic behaviour (including self-harm and
violence) over the period of the psychosis, which may
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span years. The importance of early intervention has
been emphasised in many recent reports.13-15
The relationship between duration of
untreated psychosis and long-term outcome
The onset of the first psychotic episode tends to be
preceded by functional and personality changes, as
well as a range of non-specific psychological experi-
ences.16,17 This prodromal phase may last for several
years, but once psychotic symptoms become estab-
lished, they gradually lead to increasing disturbance
of the individual’s behaviour and eventually lead to
contact with the health service. The time lag between
psychosis onset and treatment (duration of untreated
psychosis [DUP]) can be lengthy. It is suggested that
early intervention primarily targets a reduction of this
lag time and raises the issue of how the DUP could be
effectively reduced.
Methodological refinement of the onset assess-
ment18,19 have enabled studies to address the relation-
ship between DUP with better outcome in first-episode
schizophrenic patients.13,20-26 Most of these studies
have shown a correlation between a shorter DUP with
better outcome, in spite of variations in methodology
and clinical settings.20 In addition, a meta-analysis that
compared patients who have been treated with medi-
cation at particular stages in their illness with relatively
similar patients who have not been treated at those
stages indicated that the treated group achieved better
long-term outcome.4
Strictly speaking, correlational evidence does not
prove that better outcome is caused by early treatment.
It is theoretically possible that both outcome and
early treatment are mediated by a third variable.27 To
clarify this possibility, it will be necessary to conduct
controlled studies in which patients are randomised
into an early intervention group and their outcome
compared with a group without early intervention. Such
studies are difficult to arrange because of the ethical
issues that may arise. In particular, having identified
patients suffering from psychosis, it would be ethically
difficult to randomise such patients into a control group
and withhold treatment for a defined period of time
during which suffering and risks would continue to be
incurred.
Reasons behind a lengthy duration of
untreated psychosis
The DUP is commonly lengthy (12-24 months), even
in communities where psychiatric services are well
developed.13,20,22,28 This means that merely improving
service accessibility is probably not going to be suffi-
cient on its own. It is important to understand additional
obstacles that hinder timely contact between patients
and the health service. Although there is a lack of
systematic data on this issue, it is worthwhile high-
lighting some potentially important barriers.
When an individual experiences psychotic symp-
toms, the link to mental illness is seldom related to
mental illness. Often the individual is so convinced by
the sense of reality of the psychotic experience that
they do not realise that there is anything wrong with
them. In some cases, the psychotic experience causes
sufficient social disruption for the individual to be
brought to the attention of the health care system. In
other cases, such a crisis may not occur until a consider-
able amount of time has elapsed. A study investigating
the general public perception of psychotic symptoms
in Hong Kong showed that psychotic symptoms are
often regarded as merely psychological reactions to
stress rather than signs of an illness that may require
treatment.29 Such a low-key view may lead relatives
and carers to ‘wait and see’ rather than seek help early.
Much of the delay, however, can also be attributed
to an inherent reluctance by both the patient and the
family to acknowledge the possibility of a mental
disorder being the cause. This hesitation is under-
standable, as even in more liberal and progressive
societies, schizophrenia still carries considerable
stigma.30
Strategies for reducing the period of
untreated psychosis
Most early intervention programmes emphasise the
need to address some of the obstacles that keep patients
and their families from seeking help. Existing strategies
include the need to make mental health care easily
available; the need to not make patients pessimistic
about their outcome; and the need for good patient,
professional, and public education about the disease.
Accessibility of service
Most programmes emphasise a need to minimise the
effort that has to be made by the already troubled
patients and their families to come into contact with
the service. This includes convenient referral routes,
very short waiting lists, assessments at patients’ homes,
and geographically convenient locations for assessment
centres. These objectives and practices can mostly be
achieved by establishing a well-developed community-
oriented service.
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Destigmatisation
Destigmatisation could be approached by minimising
stereotyping and labelling to patients. Some programmes
suggest that separate in-patient facilities should
exist for first-episode patients and chronic patients.
This measure serves to reduce contact between first
episode patients and chronic hospitalised patients
(a biased sample of patients with a less favourable
outcome) to avoid giving first-episode patients the
impression that their illness will inevitably progress
to an unfavourable outcome.15
Education
Education involves the effective provision of information
in several different settings with different objectives—
for example, material written for the general public, at-
risk populations, relevant professional workers, patients,
and their families.
As stigmatisation is aggravated by ignorance,31,32
enhancing general public knowledge of schizophrenia
and its treatment should lead to a reduction in negative
stereotyping. Less stigmatisation could also reduce
the reluctance of psychotic patients and their families
to seek professional help. Education of the at-risk
population aims to increase individual awareness of the
potential symptoms of schizophrenia—for example, those
at risk because of genetic reasons (the siblings or the
offspring of patients have a lifetime risk of approximately
10% of becoming schizophrenic). Another approach is
to set up ‘prodrome clinics’ for individuals with prodromal
symptoms where assessment, counselling, education, and
follow-up services could be offered.
Systematic information concerning the symptoms of
schizophrenia can be provided to professional workers
likely to be in contact with individuals suffering from an
initial psychosis. These professionals include teachers,
counsellors, social workers, police officers, ministers of
religion, and general practitioners.33 Such information
could help with the early identification of patients so that
expedient referral to a specialised service could be made.
Finally, comprehensive education can be offered to
patients and their family members.34 This practice is
important for the establishment of a long-term partnership
in the clinical management of the patient and is already
present in many well-established clinical services.
Should one implement a specialised or
generic service?
One consideration is whether early intervention should
occur by a specialised programme with a dedicated
team or whether it could be integrated with routine
psychiatric services. Some aspects of intervention could
be provided by existing general psychiatric service,
especially in regions where a community-oriented
psychiatric service is in operation. Such service settings
often offer optimal accessibility for patients. However,
the fact that a long DUP is common, even in areas
where such a service exists, argues for a more intensive
and focused approach to achieve a lower DUP to be
used. With a dedicated service, issues such as mini-
mising stigmatisation and focusing on early intensive
treatment can be more thoroughly addressed.
Monitoring of prodromal symptoms
‘Prodrome clinics’ have been set up to facilitate the
early detection of those with psychotic illnesses.35
During late adolescence and early adulthood, indivi-
duals go through stressful developmental stages involv-
ing major changes in roles. Some may have difficulty
in coping with these changes and develop psycho-
logical symptoms, which may be similar to the
prodromal symptoms of schizophrenia. The specificity
of prodromal symptoms is generally relatively low36—
of all individuals experiencing such symptoms, only
a minority will eventually develop psychosis. Yet, for
those who eventually have a psychotic illness, very
early detection can be achieved. Prodrome clinics could
also serve a more general purpose in providing a
counselling service for individuals having difficulties
adjusting to their diagnosis.
Should one advance early treatment into the
prodrome phase?
Several authors have discussed the possibility of
implementing early intervention, in particular medi-
cation treatment, at the prodrome phase to prevent the
development of psychosis altogether.13,33,37 Suggested
programmes are essentially similar to those outlined
above except that screening and intervention are ex-
tended to prodromal symptoms. For instance, attempts
have been made to offer low-dose antipsychotic
medication to individuals experiencing prodromal
symptoms. The cost of intervention at the prodrome
phase is stigmatisation and side effects of medication,
in the context of a programme with relatively low
specificity (ie many false positive cases).
Although some investigators have suggested using
an extensive list of risk factors (eg family history,
neuropsychological performance, personality factors)
to enhance specificity, it is still unclear whether those
factors, when considered together, would add up to an
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aggregate risk with more discriminatory power.35 On
the other hand, the potential gain from prodromal
intervention could be a significant improvement in
outcome, or even the prevention of a psychotic illness.
Furthermore, the costs associated with medication side
effects have been substantially lowered by the advent
of the atypical antipsychotics.38 These factors have
strengthened the arguments for offering intervention
at the prodrome stage. Currently, there is an urgent
need to identify more discriminatory early markers so
that a more accurate prediction of incipient psychotic
illness can be made.13,27,37
Principles of treatment for the first episode
Medication
Proper treatment of the first psychotic episode is of
the utmost importance. Inadequate management at
this stage may foster the development of secondary
consequences which can snowball and lead to a sub-
stantial deterioration in long-term outcome. For
instance, lack of insight (ie unawareness of illness) is
a frequently encountered problem in schizophrenia. If
the degree of insight is low after the first episode, it
can lead to reduced compliance to treatment, which
in turn can increase the relapse rate and worsen the
long-term outcome. Likewise, residual psychotic
symptoms after the first episode may affect social and
occupational functioning of patients and indirectly
predispose them to stressful experiences (eg relation-
ship or occupational problems). Difficulties like these
lead to relapses and a poor long-term outcome. Hence,
the thorough and vigorous treatment of the first episode
is very important.
Previously, the medication given for first-episode
schizophrenia have followed the treatment patterns
used for patients experiencing a relapse. This treatment
has resulted in a relatively high rate of extrapyramidal
side effects. More recently, evidence has emerged
that for first-episode patients, a lower antipsychotic
dosage may be sufficient for the control of psychotic
symptoms.39 In a study of 231 consecutive patients,
the mean maximum daily dose was 4 mg haloperidol
(range, 0.5-15 mg/d); 80% responded to the medication
and 64% were in remission by the end of three months
of treatment.40 It has to be mentioned, however, that
the study was carried out in an area with a well-
developed early intervention service, and consequently,
the patients identified might have early and less intense
symptoms than the average patient.
Awareness of medication side effects is also extre-
mely important. Notable antipsychotic side effects
such as resting tremor, bradykinesia, and sedation are
often reported by patients and may contribute to non-
compliance. The adequate assessment of side effects,
as well as dosage adjustments in order to minimise them,
are key to the successful management of schizophrenia.
Once patients develop views about medication, these
can subsequently become fixed (possibly as a con-
sequence of prefrontal-type cognitive abnormalities).
The attribution of adverse consequences to taking
the medication (whether justified or not) can be very
difficult to shift at a later stage. The advent of a newer
generation of antipsychotics that have fewer motor
side effects now offer hope for better acceptance of
medication treatment by patients.38,41,42 For those
patients with florid symptoms that are resistant to
conventional antipsychotic medications, clozapine can
be offered.43
Maintenance therapy
One further issue is the length of maintenance therapy
needed after a single episode of illness. Existing data
suggests that a number of patients may not suffer a
second episode even without maintenance treatment.44
Unfortunately, it is not yet possible to identify those
who will relapse and those who will not.28 As yet, data
from double-blind controlled studies that specifically
address the optimal length of maintenance therapy are
not available.28,45 It appears, however, that continuing
medication after the first episode seems to reduce the
relapse rate in the subsequent 12 months from approxi-
mately 70% to approximately 40%.46
Management of depressive symptoms and suicide risk
Depression is common in first-episode schizophrenic
patients, with prospective studies reporting rates of
identifiable depressive syndrome of around 50% of
first episode patients.47 The actual rate of depressive
symptoms detected varied considerably between
individual studies (from 20% to 80%), depending on
the rating instruments used.48 In most cases, depressive
symptoms are worse at the time of the acute episode
and tend to subside as the psychosis comes under
control.49 If depressive symptoms persist, antidepres-
sant therapy should be commenced.49
The risk of suicide occurring is substantially
increased in first-episode schizophrenia, especially
among male patients. In a 2-year follow-up study,
5% of male patients but none of the female patients
committed suicide.47,50 Another large-scale study
observed a suicide rate of 8.8 in 1000 male patients
per year and 6.4 in 1000 female patients annually.
This study also reported that the suicide rate increases
with age.51
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Psychosocial intervention
Apart from medication, psychosocial rehabilitation
efforts are particularly important for managing negative
symptoms. Negative symptoms can be substantially
present in the first episode.12,52,53 Vigorous rehabilitation
directed at these symptoms is particularly important
in minimising secondary disabilities. Competence in
social skills is also important in sustaining a social
support network and is a crucial element in long-term
management.54 A further disability is the presence of
substantial neurocognitive deficits.8,55,56 By giving
adequate medication treatment, some of these deficits
may improve with time, but the improvement takes
longer than does the improvement in symptoms.
The efficacy of cognitive remediation programmes
in reducing neurocognitive deficits is still not estab-
lished. In general, it is known that a high level of
expressed emotion among carers of schizophrenics
is predictive of more frequent relapses. Family
behavioural therapy may be effective in modifying the
amount of expressed motion and the lower relapse rate
in selected patients. For first-episode patients, however,
data on the relationship between expressed emotion
and relapse rate are conflicting and complicated by
the potential confound of illness severity.57
Early treatment appears to be cost-effective
This review does not include a full discussion of the
cost-effectiveness analyses of early intervention pro-
grammes. There is evidence that the long-term
treatment cost for patients with a longer DUP is more
than the cost for patients with a shorter DUP.58 Full
cost-effectiveness analyses are difficult to perform
because schizophrenia is a long-term illness with many
subsequent disabilities and human costs. This makes
the indirect costs difficult to quantify.59 But cost-
effectiveness analyses, despite their obvious limita-
tions, are necessary to help focus on the potential
long-term gains offered by initially costly early-
intervention programmes.60 The better management of
a long-term illness such as schizophrenia provides a
challenge for an accountable and humane system of
health economics.59
Should early intervention for schizophrenia
be implemented?
Early intervention in cases of schizophrenia should
specifically try to reduce the DUP, which is currently
lengthy and appears to be resilient to generic com-
munity psychiatric approaches. There is a need for a
more focused, dedicated programme to achieve a
reduction in DUP. There is strong evidence for a
beneficial association between a short DUP and better
outcome. While the limitations of correlational data
are acknowledged, because of the need to reduce the
torments and risks associated with prolonged
psychosis, it seems worthwhile to support programmes
of early intervention for schizophrenia. Actions taken
at the prodrome phase are currently more contentious
because of their low specificity; their implementation
should probably await the results of further research.
However, once an early intervention programme
targeting DUP reduction is in place, it could provide
an effective basis for the future development of a
similar prodrome programme.
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